

Lecanemab

Cat. No.:	HY-P99689
CAS No.:	1260393-98-3
Target:	Amyloid- β
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lecanemab (BAN-2401) is a humanized IgG1 anti-soluble aggregated amyloid beta (A β) monoclonal antibody. Lecanemab shows activity across oligomers, protofibrils and insoluble fibrils. Lecanemab can be used for the research of Alzheimer's Disease ^{[1][2]} .
In Vitro	Lecanemab (10000, 1000, 100, 10, 1, 0.1 and 0.01 ng/mL) shows an IC ₅₀ of 0.8 nM for binding to both small and large protofibrils ^[1] . Lecanemab shows a K _d value of 2.3 μ M to A β monomers ^[1] . Lecanemab binds with small and large protofibrils with K _{D1} values of 0.97 and 0.16 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Söderberg L, et al. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. *Neurotherapeutics*. 2022 Oct 17.

[2]. McDade E, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. *Alzheimers Res Ther*. 2022 Dec 21;14(1):191.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA